Company news
Amylyx Pharmaceuticals, Inc. news in 2022
Amylyx Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
November 21, 2022
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 9, 2022
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
November 2, 2022
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
October 10, 2022
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
October 5, 2022
Amylyx Pharmaceuticals Announces Launch of Public Offering
October 3, 2022
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
September 28, 2022
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
September 13, 2022
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds
September 11, 2022
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
September 6, 2022
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
September 1, 2022
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 10, 2022
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
August 2, 2022
Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS
July 28, 2022
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
July 17, 2022
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
July 5, 2022
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
July 4, 2022
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
June 12, 2022
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
June 2, 2022
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
May 25, 2022
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
May 15, 2022
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
May 11, 2022
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
May 4, 2022
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
April 1, 2022
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
March 29, 2022
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
March 29, 2022
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
March 27, 2022
Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
March 17, 2022
Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
February 24, 2022
Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel
February 22, 2022
Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022
February 15, 2022
Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS
February 2, 2022
Calls in 2022
Decks in 2022
- ENDO 2022
Conference · 15 slides · Jun 11, 2022